Bioequivalence Study Of Verapamil

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 7% of the time (318 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2008-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: condition possiblyhypertensionpossibly affectingaffecting drugpurpose
  Phrases that lowered it: healthybioequivalencesinglecrossoveropen label
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: crossover (lowers risk) · Design
• Sponsor's past termination rate: 14.7% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Responsible party: not given (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 246 (raises risk) · Sponsor's track record
• Maximum age: 55 (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 15.1% (lowers risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past trials: 360 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects NCT01289509 · started 2010 · scored riskier than 0% of active trials completed
• A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet NCT01943487 · started 2009 · scored riskier than 0% of active trials completed
• Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects NCT06354556 · started 2024 · scored riskier than 1% of active trials completed
• Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. NCT01437384 · started 2011 · scored riskier than 4% of active trials completed
• Comparative Bioavailability Study of Two Oral Formulations of Clopidogrel NCT01447563 · started 2008 · scored riskier than 0% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.